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AbstrAct
Objective HIV transmission is ongoing among men who 
have sex with men (MSM) in the UK. Sex without a condom 
(condomless sex, CLS) is the main risk factor. We investigated 
the prevalence of and factors associated with types of CLS.
Methods Cross-sectional questionnaire study in UK HIV 
clinics in 2011/2012 (ASTRA). MSM diagnosed with HIV 
for ≥3 months reported on anal and vaginal sex, CLS with 
HIV-serodifferent partners (CLS-D) and CLS with HIV-
seroconcordant (CLS-C) partners in the previous 3 months. 
Mutually exclusive sexual behaviours were as follows: (1) 
Higher HIV risk CLS-D (not on antiretroviral therapy (ART) or 
clinic-recorded viral load(VL) >50 c/mL), (2) Other CLS-D, (3) 
CLS-C without CLS-D, (4) Condom-protected sex only and 
(5) No anal or vaginal sex. Associations were examined of 
sociodemographic, HIV-related, lifestyle, and other sexual 
measures with the five categories of sexual behaviour. 
We examined the prevalence of higher HIV risk CLS-D 
incorporating (in addition to ART and VL) time on ART, ART 
non-adherence, and recent sexually transmitted infections 
(STIs).
results Among 2189 HIV-diagnosed MSM (87% on ART), 
prevalence of any CLS in the past 3 months was 38.2% 
(95% CI 36.2% to 40.4%) and that of any CLS-D was 
16.3% (14.8%–17.9%). The five-category classification 
was as follows: (1) Higher HIV risk CLS-D: 4.2% (3.5% 
to 5.2%), (2) Other CLS-D: 12.1% (10.8% to 13.5%), 
(3) CLS-C without CLS-D: 21.9% (20.2% to 23.7%), (4) 
Condom-protected sex only: 25.4% (23.6% to 27.3%) 
and (5) No anal or vaginal sex: 36.4% (34.3% to 38.4%). 
Compared with men who reported condom-protected sex 
only, MSM who reported any CLS in the past 3 months had 
higher prevalence of STIs, chemsex-associated drug use, 
group sex, higher partner numbers, and lifetime hepatitis C. 
Prevalence of higher HIV risk CLS-D ranged from 4.2% to 
7.5% according to criteria included.
conclusion CLS was prevalent among HIV-diagnosed 
MSM, but CLS-D with higher HIV transmission risk was 
overall low. CLS-D is no longer the most appropriate 
measure of HIV transmission risk behaviour among people 
with diagnosed HIV; accounting for VL is important.
IntrOductIOn
HIV transmission is ongoing among men who have 
sex with men (MSM) in the UK, despite continfigued 
prevention efforts, universal access to HIV care, 
high antiretroviral therapy (ART) uptake and high 
levels of HIV plasma viral load (VL) suppression in 
the diagnosed population.1 HIV incidence is driven 
by patterns of sexual risk behaviour among HIV-di-
agnosed, HIV-undiagnosed, and HIV-negative 
MSM.2 Given the increase in uptake of HIV testing 
and ART use in the past decade, sustained HIV 
incidence among MSM points to increasing sexual 
risk behaviours during this period.3 The majority of 
HIV transmissions among MSM in the UK derive 
from men with as yet undiagnosed HIV.4 5 However, 
modelling studies estimate that sizeable proportions 
of transmissions originate from HIV-diagnosed 
individuals (estimated 18% in the UK4 and 29% 
in the Netherlands6). Over the past decade, diag-
noses of other STIs, such as gonorrhoea, syphilis, 
and genital herpes, have also increased considerably 
among MSM in the UK, and are prevalent among 
HIV-diagnosed MSM.7
Among HIV-diagnosed people, the primary indi-
cator of HIV transmission risk is anal or vaginal 
sex without a condom (condomless sex,CLS), in 
particular, with partners who are HIV-negative or 
do not know their HIV serostatus (CLS with HIV-se-
rodifferent partners,CLS-D). The concept of ‘high 
risk sex’ has evolved substantially over the past two 
decades: first, with the introduction of combination 
ART for the treatment of HIV (1995/1996), and 
second, with the high-publicity ‘Swiss Statement’ 
(2008) that asserted (with caveats) that an HIV-pos-
itive person on ART with viral suppression is 
not sexually infectious8 and, subsequently, with 
increasing evidence from observational studies and 
randomised controlled trials on the crucial role of 
HIV VL suppression on reducing HIV transmis-
sion.9–11 There is now concrete evidence that the 
risk of HIV transmission during CLS-D among 
MSM is extremely low when the HIV-positive 
partner is on virally suppressive ART.12 13 Results 
from recent trials (since 2012) have also shown 
the substantial protective effect conferred by oral 
pre-exposure prophylaxis (PrEP) in reducing the 
risk of HIV acquisition among HIV-negative indi-
viduals.14–16 As a result, the concept of high-risk 
sex will further evolve with additional evidence 
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and use of PrEP. CLS-D may no longer be the most appropriate 
measure of higher risk CLS in the context of HIV transmission 
for HIV-diagnosed individuals. Understanding the prevalence 
and drivers of various types of CLS among MSM living with 
HIV warrants further study and is important in informing clin-
ical care and HIV/STI prevention strategies.
Few studies have assessed the prevalence of different types 
of CLS among representative samples of HIV-diagnosed MSM 
in the UK or examined CLS with an appreciable risk of HIV 
transmission (accounting for ART use and VL level). This study 
describes the prevalence and factors associated with recent CLS 
among HIV-diagnosed MSM in the UK, including CLS with 
HIV-serodifferent partners that could confer higher risk of HIV 
transmission, and other CLS with HIV-serodifferent and HIV-se-
roconcordant partners.
MEthOds
AstrA study
The Antiretrovirals, Sexual Transmission Risk and Attitudes 
(ASTRA) study recruited HIV-diagnosed adults attending 
eight hospital HIV outpatient clinics in the UK from 2011 
to 2012.2 Participants completed a confidential, self-admin-
istered questionnaire that sought information on sociodemo-
graphic, HIV-related, health and lifestyle factors, as well as 
sexual behaviours. Consent to participate included permission 
to collect latest CD4 count and HIV plasma VL from clinic 
records (latest value available to the participant). Current 
ART use, date of starting ART, and ART non-adherence in the 
past 3 months were defined according to self-report on the 
questionnaire. Men who identified as gay or bisexual or who 
reported sex with men in the previous three months were clas-
sified as MSM. Participants were asked about the use of any 
of the following recreational drugs in the past 3 months: acid/
LSD/magic mushrooms, anabolic steroids, cannabis, cocaine, 
crack cocaine, codeine, crystal methamphetamine, ecstasy 
(MDMA), GHB/GBL (liquid ecstasy), heroin, ketamine, khat 
(chat), mephedrone, morphine, opium, poppers (nitrites), 
speed (amphetamine) and erectile dysfunction drugs (such as 
Viagra, Cialis and similar pro-erection drugs). Polydrug use was 
defined as the use of ≥4 drugs in the previous three months. 
Chemsex-associated drug use was defined as the use of one or 
more of the following: mephedrone, GHB/GBL, and crystal 
methamphetamine.17 Social support was assessed using a modi-
fied version of the Duke-UNC Functional Social Support Ques-
tionnaire.18 Harmful alcohol consumption (that increases the 
risk of harmful consequences to the user or others) was defined 
as a score of ≥6 on a modified version of the WHO AUDIT-C 
(first two questions only).19
sexual behaviours
The questionnaire enquired about the following sexual 
behaviours in the previous 3 months: (1) any anal or vaginal sex, 
(2) any CLS (anal or vaginal sex without a condom), (3) any CLS 
with HIV-serodifferent partners (CLS-D, CLS with a man or 
woman who did not have HIV or whose HIV status the partic-
ipant did not know) and (4) any CLS with HIV-seroconcordant 
partners (CLS-C, CLS with a man or woman the participant 
knew also had HIV). These four measures provided the overall 
estimates of any sex, any CLS, any CLS-D, and any CLS-C in the 
past 3 months.
Using these four variables and with additional information 
on ART use and clinic VL level, it was possible to then classify 
each participant into one of five mutually exclusive categories 
of sexual behaviour in the past 3 months. The categories are 
presented below:table 1
Therefore, according to this five-category variable, a man who 
had CLS with other HIV-positive men, but not with HIV-negative 
or HIV-unknown status men, was classified as ‘CL20S-C without 
CLS-D’ (category 3); a man who reported anal or vaginal sex but 
did not report either CLS-D or CLS-C was classified as having 
condom-protected sex only (category 4).
Other sexual behaviours, stIs and attitudes
Self-reported STI diagnosis in the past 3 months included 
syphilis, gonorrhoea, chlamydia, lymphogranuloma venereum 
(LGV), new hepatitis B or C, new or recurrent genital herpes 
or warts, trichomonas, and non-specific urethritis/non-gono-
coccal urethritis (NSU/NGU). Participants were asked to report 
the total number of partners (men and women) they had sex 
with in the past 3 months, the total number of HIV-negative or 
HIV-unknown serostatus partners they had sex with without 
a condom in the previous 3 months (CLS-D partners) and the 
total number of HIV-positive partners participants had sex with 
without a condom in the previous 3 months (CLS-C partners). In 
the past 3 months, the following were also assessed: group sex 
(with more than one other person on the same occasion) and use 
of the internet to find sex. Participants rated their agreement to 
statements on condom use and HIV transmission on a 5-level 
Likert scale (from ‘strongly agree’ to ‘strongly disagree’). These 
statements were as follows: (1) difficulty negotiating condom 
use (‘I find it difficult to discuss condom use with a new sexual 
partner’), (2) lower condom use with casual partners (‘I am less 
likely to use a condom with a casual partner’) and (3) worry 
about HIV transmission (‘I am worried that I could have infected 
someone else with HIV in the past few months’). Responses 
rated ‘strongly agree’ and ‘tend to agree’ were combined into 
one category (versus ‘undecided’, ‘tend to disagree’ and ‘strongly 
disagree’). Participants also reported the total number of new 
sexual partners in the past year and whether they had ever 
received a diagnosis of hepatitis C. Sexual positioning (insertive 
or receptive partner) and withdrawal before ejaculation were 
assessed among MSM who had CLS-D in the past 3 months only.
table 1 
sexual behaviour category in the past 
3 months (mutually exclusive) definition
1. Higher HIV risk CLS-D CLS with HIV-negative or HIV-unknown 
serostatus partners (CLS-D) and 
either: not on ART at the time of the 
questionnaire or has latest clinic VL 
>50 c/mL. Includes n=8 participants who 
reported having CLS without specifying 
their partner(s) HIV serostatus
2. Other CLS-D Any other CLS with HIV-serodifferent 
partners (but not CLS-D higher HIV risk). 
Includes n=23 participants who reported 
having CLS without specifying their 
partner(s) HIV serostatus
3. ‘CLS-C without CLS-D’ CLS with HIV-seroconcordant (other HIV-
positive) partners only (CLS-C), with no 
CLS-D partners
4. Condom-protected sex Condom-protected sex only
5. No anal or vaginal sex
ART, antiretroviral therapy; CLS, condomless sex; N=31 participants with 'possible 
ClS-D' (reported having CLS but did not specify partner(s) serostatus) were included 
as CLS-D in this classification20.
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Additional definitions of higher hIV-risk cLs-d
We sought to assess alternative definitions of higher HIV risk 
CLS with HIV-serodifferent partners (CLS-D) by incorporating 
factors additional to ART use and VL level. Factors were selected 
on the basis of any evidence that these may compromise low 
HIV infectiousness even if the participant was on ART with last 
recorded VL ≤50 c/mL. Self-reported factors (in addition to 
reporting CLS-D and either not being on ART or having latest 
clinic VL ≥50 c/mL) included the following: (1) started ART ≤9 
months ago, (2) ART non-adherence (missing ≥2 consecutive 
days of ART on ≥2 occasions in past 3 months) and (3) diagnosis 
of STI (other than HIV) in the past 3 months.
statistical methods
Exclusion of recently diagnosed participants
To improve validity of sexual behaviour questions with a 3-month 
recall, we excluded MSM who were diagnosed three or fewer 
months prior to the date of the questionnaire completion (n=59).
Prevalence of sexual behaviours
Among all MSM, the prevalence (and 95% CI) of any sex, any 
CLS, any CLS-D, and any CLS-C was assessed in the previous 
3 months. The prevalence of specific sexual behaviours in the 
past 3 months was then assessed according to the mutually exclu-
sive five-category variable.
Those who reported not having any anal or vaginal sex in the past 
3 months were then excluded, and the prevalence of any CLS, any 
CLS-D, and any CLS-C was assessed among the remaining MSM 
(who reported any sex in the past 3 months.) Associations were 
then examined between the mutually exclusive variable of sexual 
behaviour and sociodemographic, lifestyle, HIV-related factors and 
other sexual behaviours (among MSM who had anal or vaginal sex 
only). χ2 tests, χ2 tests for trend, or Kruskal-Wallis tests were used 
to compare across the four categories reporting anal or vaginal sex 
in the past 3 months only.
Additional definitions of higher hIV risk cLs-d
We assessed the prevalence of various definitions of higher HIV 
risk CLS-D among all MSM with available data, by incorporating 
different criteria. This resulted in eight possible definitions of 
higher HIV risk CLS-D, which are defined explicitly in figure 3.
rEsuLts
AstrA demographics
A total of 3258 HIV-diagnosed men and women completed 
the questionnaire (response rate 64%).2 This analysis reports 
on 2189 MSM diagnosed with HIV for ≥3 months prior to 
ASTRA, of whom 95% identified as gay, 5% as bisexual, and 
90% as white; 44% had a university degree and 61% were 
employed. Mean age was 46 years (SD 9.4) and median time 
since HIV diagnosis was 10 years (IQR 5–16). Almost 87% 
were on ART, of whom 89% had clinic-recorded VL ≤50 c/mL 
at the last known test (93% had VL ≤200 c/mL). The timing 
of last available clinic VL result was ≤2 months before ques-
tionnaire (n=1088,50.0%), 2–4 months before (n=562,25.8%), 
4–6 months before (n=338,15.5%), 6–12 months before 
(n=173,7.9%) and ≥12 months before (n=14,0.6%).
Prevalence of sexual behaviours and association with other 
factors
Among all 2189 HIV-diagnosed MSM, overall prevalence esti-
mates for sexual behaviour measures in the past 3 months were 
as follows: any anal or vaginal sex: 63.6% (95% CI 61.5% to 
65.6%, n/N=1392/2189), any CLS (with HIV-serodifferent 
and/or HIV-seroconcordant partners): 38.2% (36.2% to 40.4%, 
836/2189), any CLS-D: 16.3% (14.8% to 17.9%, 357/2189) 
and any CLS-C: 28.7% (26.8% to 30.6%, 628/2189).
When classifying all 2189 MSM according to the single vari-
able of five mutually exclusive categories, the prevalence of 
sexual behaviours in the past 3 months was as follows: (1) higher 
HIV risk CLS-D: 4.2% (95% CI 3.5% to 5.2%, n=93), (2) other 
CLS-D: 12.1% (10.8% to 13.5%, n=264), (3) ‘CLS-C without 
CLS-D’: 21.9% (20.2% to 23.7%, n=479), (4) condom-pro-
tected sex only: 25.4% (23.6% to 27.3%, n=556) and (5) no 
anal or vaginal sex: 36.4% (34.3% to 38.4%, n=797).
A total of 1392 MSM reported having anal and/or vaginal sex 
in the previous 3 months; 1360 had anal sex with men only, 11 
had anal or vaginal sex with women only and 21 had anal or 
vaginal sex with both men and women. The prevalence of any 
CLS in this group was 60.1% (57.5% to 62.6%, n/N=836/1392), 
that of any CLS-D was 25.6% (23.4% to 28.0%, 357/1392) 
and that of any CLS-C was 45.1% (42.5% to 47.7%, 628/1392).
Table 2 shows the associations of sociodemographic, life-
style, and HIV-related factors with the mutually exclusive vari-
able of sexual behaviour (n=2189 MSM). Compared with the 
four sexually active groups (1–4), men who did not have anal 
or vaginal sex in the previous 3 months (group 5) were older, 
diagnosed with HIV for longer, less likely to have a university 
degree or employment, more likely to be born in the UK, and 
less likely to have a stable partner. There were some differences 
in socio-demographic factors between the four sexually active 
groups in terms of age, length of time living with diagnosed 
HIV, financial hardship and stable partner status; MSM who 
had higher HIV risk CLS-D were more likely to be younger, to 
have been diagnosed for a shorter period of time, and to report 
financial hardship, compared with those who had other CLS-D, 
‘CLS-C without CLS-D’, or condom-protected sex only. Men in 
the two CLS-D groups and those who reported condom-pro-
tected sex were much more likely than those in the CLS-C group 
to have an HIV-serodifferent stable partner. Conversely, those 
in the CLS-C group were more likely to have an HIV-positive 
stable partner. In terms of lifestyle factors, There were marked 
differences across the four groups in terms of lifestlye factors, 
MSM in the three CLS groups were substantially more likely to 
report recreational drug and polydrug use in the past 3 months 
compared with those who had condom-protected sex. The prev-
alence of harmful alcohol consumption was also significantly 
higher among MSM who had higher HIV risk CLS-D compared 
with the other three sexually active groups (p<0.05 for all above 
factors compared across groups 1 to 4). When excluding cannabis 
and nitrites from the definition of polydrug use, the prevalence 
of using ≥4 drugs in the past 3 months was highest among MSM 
who had ‘CLS-C without CLS-D’ (44.6%), followed by those 
who had higher HIV risk CLS-D (32.7%), other CLS-D (29.2%), 
and condom-protected sex (19.1%), and was lowest for those 
who did not have sex (15.9%). These patterns of associations 
were broadly similar after adjustment for age, time since HIV 
diagnosis, and stable partner status (data not shown).
number of sexual partners
Figure 1 shows the distribution of the mutually exclusive sexual 
behaviour variable (groups 1 to 4 only) according to the total 
number of sexual partners participants reported in the past 
3 months (n=1392 MSM who had anal or vaginal sex in the 
past 3 months, of whom 1357 had information on number of 
sexual partners). Prevalence of higher HIV risk CLS-D and other 
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CLS-D increased substantially with higher total number of part-
ners in the past 3 months.
Information on number of CLS-D partners was available for 
320 (of 357) MSM who had CLS-D in the past 3 months; of 
the 84 MSM who had higher HIV risk CLS-D, 52.4% had only 
one CLS-D partner, 31.0% had two to four CLS-D partners, 
and 16.7% had five or more CLS-D partners; the corresponding 
proportions for 236 MSM who had ‘other CLS-D’ were 57.6%, 
27.1%, and 15.2%. Information on number of CLS-C partners 
was available for 476 (of 479) MSM who had ‘CLS-C without 
CLS-D’; 59.4% had one CLS-C partner, 24.6% had two to four 
CLS-C partners and 16.0% had five or more CLS-C partners in 
the past 3 months.
Other sexual behaviours, stIs and attitudes
Among 236 MSM who reported any other STI diagnosis in 
the past 3 months, 73.3% had one STI and 26.7% had two or 
more STIs. The majority (58.4%) of 310 responses were for 
bacterial STIs (syphilis, gonorrhoea, chlamydia, and LGV), 
11.9% were for new or recurrent genital herpes, 9.9% were for 
new or recurrent genital warts, 7.1% were for new hepatitis B 
or C diagnosis and the remaining were for NSU/NGU and other 
(unspecified) STIs.
Figure 2 shows the prevalence (and 95% CIs) of other sexual 
behaviours, STIs, attitudes towards condom use and HIV trans-
mission, among 1392 MSM who reported any anal or vaginal 
sex only. Substantial differences were observed between the four 
sexually active groups on all sexual behaviours, STIs and attitudes. 
Compared with MSM who had CLS (groups 1–3), those who 
had condom-protected sex (group 4) had much lower prevalence 
of chemsex-associated drug use, STIs, group sex, high partner 
numbers,  and use of the internet to find sex, and were less likely 
to report difficulty in using condoms and worries about HIV 
transmission. The prevalence of high partner numbers, group 
sex, use of the internet to find sex, and reporting transactional 
sex in the past 3 months was highest among men having higher 
HIV risk CLS-D (group 1) and those having other CLS-D (group 
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Figure 1 Distribution of sexual behaviour according to number of 
total sexual partners in the past 3 months (n=1392 HIV-diagnosed 
MSM reporting any anal or vaginal sex in the past 3 months). CLS, 
condomless sex; CLS-C, CLS with HIV-seroconcordant; CLS-D, CLS with 
HIV-serodifferent partners.
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2), followed by those who had ‘CLS-C without CLS-D’ (group 
3). Men reporting any CLS-D (groups 1 and 2) were also more 
likely than the other two sexually active groups to report diffi-
culty in discussing or using condoms with new partners. Almost 
23% of MSM who had higher HIV risk CLS-D and 17.3% of 
those who had other CLS-D were worried they could have trans-
mitted HIV recently. Prevalence of chemsex-associated drug use 
in the past 3 months and of lifetime hepatitis C diagnosis was 
highest for MSM who had ‘CLS-C without CLS-D’ (group 3). 
These patterns of associations were similar after adjustment for 
age, time since HIV diagnosis, and stable partner status (data not 
shown).
hIV risk reduction sexual behaviours during cLs-d
The prevalence of sexual positioning and withdrawal prior to 
ejaculation was assessed among 314 MSM who reported any 
CLS-D (higher HIV risk or other CLS-D); 28.0% (95%CI 23.3% 
to 33.3%, n=88) reported being the insertive partner and ejac-
ulating inside, 29.3% (24.5% to 34.6%, n=92) reported  being 
insertive but never ejaculating inside, 40.1% (34.9% to 45.7%, 
n=126) reported always being the receptive partner, and 2.5% 
(1.3% to 5.1%, n=8) reported having CLS-D with women only 
in the past 3 months. There were no significant differences in the 
prevalence of sexual positioning or ejaculation between MSM 
who reported higher HIV risk CLS-D and those who reported 
other CLS-D (insertive with ejaculation: 24.1% vs 29.4%, 
respectively; insertive without ejaculation: 25.3% vs 30.7%; 
receptive only: 48.2% vs 37.2%, Fisher's exact test, p=0.392).
Additional definitions of higher hIV risk cLs-d
Figure 3 shows additional definitions for higher HIV risk CLS-D 
in the previous 3 months, according to various criteria incor-
porated. The main definition required reporting CLS-D in the 
previous 3 months with at least one of two additional factors: 
not on ART or clinic-recorded VL >50 c/mL. In further defi-
nitions, the set of additional factors that could confer higher 
HIV risk CLS-D was widened to include the following: started 
ART months ago, non-adherence to ART, and other diagnosed 
STIs in the past 3 months. The prevalence of each definition of 
higher HIV risk CLS-D in the previous 3 months was assessed 
among 2189 HIV-diagnosed MSM, and  ranged from 4.2% to 
7.5% depending on criteria included. For example, 7.5% of all 
HIV-diagnosed MSM were classified as having higher HIV risk 
CLS-D if they reported having CLS-D in the previous 3 months 
Figure 2 Associations between other sexual behaviours, STIs, attitudes to condom use and single variable of sexual behaviour in the past 3 months 
(n=1392 HIV-diagnosed MSM reporting any anal or vaginal sex in the past 3 months).
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and either were not on ART or had latest VL >50 c/mL or 
started ART <9 months ago or reported non-adherence to ART 
or another diagnosed STI. Compared with the prevalence of any 
CLS-D in the past 3 months (16.3% of 2189 MSM), the preva-
lence of higher HIV risk CLS-D was lower by 53%–74% in rela-
tive terms. Results were similar when VL cut-off was increased 
to >200 c/mL (prevalence ranged from 3.5% to 7.1%).
dIscussIOn
In this large multicentre UK study of HIV-diagnosed MSM, over 
a third reported having CLS in the previous 3 months: 16% had 
CLS with HIV-negative or unknown status partners (CLS-D) and 
22% had CLS with HIV-seroconcordant partners only (‘CLS-C 
without CLS-D’). Only 4.2% of MSM had CLS-D while either 
not on ART or with detectable VL, and they were, therefore, 
classified as having CLS-D with higher risk of HIV transmission. 
Compared with men who reported condom-protected sex only, 
MSM who reported any type of CLS in the past 3 months had 
higher prevalence of STIs, recreational and chemsex-associated 
drug use, group sex, higher partner numbers, and lifetime hepa-
titis C diagnosis.
Similar prevalence estimates of CLS (CLS-D and CLS-C) have 
been observed in studies of HIV-diagnosed MSM recruited from 
HIV-outpatient clinics in the UK21–25 and the USA.26–29 Our 
results are also in line with baseline data from the START trial of 
early versus deferred ART initiation; CLS-D in the past 2 months 
was 15.1% among ART-naive HIV-diagnosed MSM in the Euro-
pean sample (n/N=177/1172), and 12.1% when excluding MSM 
diagnosed in the past 3 months (as in this ASTRA analysis).30 CLS 
with other HIV-positive partners only was also prevalent in our 
study, suggesting actual or perceived serosorting (selecting sexual 
partners based on HIV status). The consistent prevalence of CLS 
estimates between the aforementioned clinic-based studies and 
ASTRA is encouraging in supporting our ability to reliably and 
repeatedly measure such behaviours and capture trends. These 
results also suggest that there has not been an increase in the 
prevalence of CLS-D among HIV-diagnosed MSM in the UK 
during the past decade.CLS with HIV-serodifferent partners 
(CLS-D) denoted high-risk sex for HIV transmission prior to 
the emergence of conclusive evidence on the extremely low 
risk of HIV transmission when the HIV-diagnosed partner is 
on suppressive ART.11 12 Coupled with changes in treatment 
guidelines recommending ART initiation at any CD4 count,31 
these important results may affect trends in CLS among HIV-di-
agnosed MSM. In ASTRA, the prevalence of higher HIV risk 
CLS-D in the past 3 months was overall low, ranging from 4.2% 
when considering CLS-D while not on ART or with detectable 
VL, to 7.5% when additionally considering time since started 
ART, non-adherence, or other STI co-infections. There is no 
other evidence to date on the prevalence of higher HIV risk CLS 
with HIV-serodifferent partners among HIV-diagnosed MSM in 
the UK. Recently, a number of US studies have estimated the 
prevalence of CLS-D when VL is not suppressed among HIV-di-
agnosed MSM outpatients. In the previous 3 months, estimates 
of higher HIV risk CLS-D were as follows: 18.9% in the Adoles-
cent Medicine Trials Network (n=991 MSM, defined as CLS-D 
and latest clinic-recorded VL ≥200 c/mL)w1 and 34% in the 
international HPTN063 cohort study (n=200, defined as CLS-D 
and ‘detectable VL’ or other STI)w2. In the previous 6 months, 
estimates of higher HIV risk CLS-D were as follows: 3.4% in 
the HIV Outpatient Study (n=902, defined as insertive CLS-D 
and VL ≥400 c/mL)w3 and 34% in the baseline survey of Fenway 
Health (n=201, CLS-D and either VL >75 c/mL or diagnosis 
of gonorrhoea, syphilis, or chlamydia in the past year)w4. Finally, 
in the past year, prevalence of CLS-D with higher HIV transmis-
sion risk was 6.0% in the US nationally representative Medical 
Monitoring Project (n=1897, defined as CLS-D and one or 
more VL ≥400 c/mL in the past 12 months)w5. In ASTRA, when 
additionally including sexual positioning in the definition, 
the prevalence of higher HIV risk CLS-D (defined as insertive 
CLS-D and either not on ART or latest clinic VL ≥50 c/mL) was 
1.8% (95% CI 1.4% to 2.5%). The disparity in estimates is due 
to differences in definitions, study design and methodology, and 
method of survey administration as well as potential genuine 
differences across population/demographic groups. In particular, 
study eligibility criteria varied, as certain studies required partic-
ipants to be diagnosed for at least 12 monthsw6 w7, which may 
have underestimated the prevalence of higher HIV risk CLS-D 
by excluding people who were not on stable ART. Conversely, 
other studies excluded participants who did not report CLS w2 w4 
leading to higher prevalence estimates.
It is still unclear which factors, additional to ART use and 
VL level, should be incorporated in clinical and epidemiolog-
ical definitions of sex with higher risk of HIV transmission, 
Figure 3 Prevalence (95% CI) of higher HIV transmission risk CLS-D among 2189 HIV-diagnosed MSM according to criteria incorporated (ART 
status, viral load level, time since started ART, ART non-adherence, and self-reported other STI diagnosis in past 3 months).
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particularly in the context of CLS with multiple HIV-serodif-
ferent partners. There is also a need for better understanding 
of the effect of different levels of non-adherence on the likeli-
hood of viral rebound to a level that will significantly impact 
HIV transmission risk. Additional longer-term follow-up from 
the PARTNER study of HIV-serodifferent couples12 will also be 
crucial in providing precise estimates of HIV transmission risk 
among MSM in the context of effective ART. Such information 
is important in refining current guidelines and in helping HIV-di-
agnosed individuals and their partners make informed decisions 
on having CLS-D safely. Standardised definitions of higher HIV 
risk CLS-D would be useful for epidemiological studies of behav-
ioural surveillance.
A substantial proportion of men engaging in higher HIV risk 
CLS-D (and in other CLS-D) in ASTRA reported chemsex-asso-
ciated drug use, group sex, and high numbers of sexual partners. 
A strong association was also observed between the total number 
of sexual partners in the past 3 months and prevalence of CLS 
and CLS-D in the past 3 months. This may emphasise the chal-
lenge of maintaining consistent condom use and accurately 
ascertaining partners’ HIV serostatus in the context of high 
partner numbers. Consistent with other studies12 26 w4, results 
from ASTRA may indicate use of perceived risk reduction strate-
gies during CLS-D, such as being the receptive partner and with-
drawal before ejaculation.
While it is encouraging that a sizeable proportion of HIV-di-
agnosed MSM in ASTRA restrict CLS to HIV-positive partners 
only, this does not eliminate the risk of other STIs. In fact, MSM 
who had ‘CLS-C without CLS-D’ had the highest prevalence of 
lifetime hepatitis C diagnosis and of chemsex-associated drug 
use. During the past decade, increased diagnoses of other STIs 
among HIV-diagnosed MSM in the UK have coincided with 
the emergence of sexually transmissible enteric infectionsw7. 
These overlapping epidemics suggest that sexual networks of 
HIV-diagnosed MSM engaging in serosorting may contribute to 
transmission of other STIs in the UK. In terms of assessing and 
monitoring risk of transmission of STIs among HIV-diagnosed 
MSM, ‘any condomless sex’ is likely to be the most relevant 
measure.
ASTRA is the largest questionnaire study of HIV-diagnosed 
individuals in the UK to date; the study population can be 
considered representative of HIV-diagnosed MSM in the UK, as 
access to healthcare is universal and over 95% of HIV-diagnosed 
people access specialist HIV services. The response rate (64%) is 
satisfactory and comparable to earlier similar studies.22 23 25 There 
were no significant differences in VL or CD4 cell count between 
responders and those who did not respond but consented to 
participate.2 Our study does have some limitations. Self-reported 
sexual behaviour may be subject to error and bias; underreporting 
of CLS is possible and may have led to underestimation of prev-
alence. A single clinic-recorded plasma VL measure was used in 
the definition of higher HIV risk CLS-D. Although this measure 
was the latest VL result available to the participant, it occurred 
at a variable time in relation to the 3-month recall period for 
sexual behaviour; VL status may have changed over this period 
for some participants. The length of time with viral suppression 
specifically could not be incorporated. Among HIV-diagnosed 
MSM who had CLS with other HIV-positive partners only, it 
was not possible to ascertain whether a partner’s HIV-positive 
serostatus was assumed or known with confidence.
Although ASTRA was conducted after the 2008 Swiss state-
ment, when expert opinion on reduced risk of HIV transmission 
with suppressed VL was widely publicised, it was conducted prior 
to publication of results from HPT05211 and PARTNER.12 The 
sexual behaviour of HIV-diagnosed MSM, as well as the prev-
alence of higher HIV risk CLS-D, may change with increasing 
awareness of results from these studies.
cOncLusIOns
In conclusion, among HIV-diagnosed MSM in the UK, the prev-
alence of CLS in the previous 3 months was relatively high, but 
in line with results from similar UK studies in the past decade. 
The high prevalence of CLS with other HIV-positive partners 
may indicate active serosorting and warrants further attention 
as transmission of other STIs is high among people with HIV. 
Although 1 in 6 HIV-diagnosed MSM reported having CLS 
with HIV-serodifferent partners (CLS-D), <1 in 14 reported 
CLS-D with an appreciable risk of HIV transmission. As ART 
use expands, it remains crucial to promote sustained high ART 
adherence, regular VL monitoring and ongoing awareness of 
personal VL levelw8 w9. In order for behavioural studies on HIV 
transmission to be representative of the developments in under-
standing of HIV transmission and prevention, there is a need 
to move away from definitions of ‘unsafe’ or ‘risky’ sex based 
solely on CLS with HIV-serodifferent partners among people 
with diagnosed HIV. Incorporating ART status, latest VL, and 
other factors that impact strongly on HIV transmission will 
ensure research measures are based on contemporary evidence.
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